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Drug discoveryGrowing evidences show that epigenetic mechanisms play crucial roles in the genesis and progression of many
physiopathological processes. As a result, research in epigenetic grew at a fast pace in the last decade. In partic-
ular, the study of histone post-translational modiﬁcations encountered an extraordinary progression and many
modiﬁcations have been characterized and associated to fundamental biological processes and pathological con-
ditions. Histonemodiﬁcations are the catalytic result of a large set of enzyme families that operate covalent mod-
iﬁcations on speciﬁc residues at the histone tails. Taken together, these modiﬁcations elicit a complex and
concerted processing that greatly contribute to the chromatin remodeling and may drive different pathological
conditions, especially cancer. For this reason, several epigenetic targets are currently under validation for drug
discovery purposes and different academic and industrial programs have been already launched to produce
the ﬁrst pre-clinical and clinical outcomes. In this scenario, computer-aided molecular design techniques are of-
fering important tools, mainly as a consequence of the increasing structural information available for these tar-
gets. In this mini-review we will brieﬂy discuss the most common types of known histone modiﬁcations and
the corresponding operating enzymes by emphasizing the computer-aided molecular design approaches that
can be of use to speed-up the efforts to generate new pharmaceutically relevant compounds.
© 2015 Andreoli and Del Rio. Published by Elsevier B.V. on behalf of the Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license
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In the last decades, major efforts have been done in genetics though
it is evident that unraveling complex biological mechanisms like canceris and Photoreactivity, National
Italy. Tel.: +39 051 6398308;
lrio@isof.cnr.it (A. Del Rio).
evier B.V. on behalf of the Research N
y/4.0/).requires a larger framework of research that recently evolved toward
the better understanding of the immune system regulation [1], the re-
discovery of metabolism [2] and, importantly, the role of epigenetics
[3]. The term epigenetics refers to themechanisms of temporal and spa-
tial control of gene activity that do not entail modiﬁcation of the DNA
sequence but inﬂuence the physiological and pathological development
of an organism. Themolecularmechanisms bywhich epigenetic chang-
es occur are complex and cover awide range of processes [4]. Epigenetic
mechanisms can occur at biochemical level in three different ways:etwork of Computational and Structural Biotechnology. This is an open access article under
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be the object of this mini-review, as well as the molecular recognition
of non-catalytic readers of histones [5], ii) through the DNA methyla-
tion, i.e. the methylation of cytosines to 5-methylcytosines, which is
the object of recent reviews [6–8], and iii) through regulation of gene
expression by non-coding RNA (ncRNA), which is also an emerging
topic of research, covered by recent reviews [9–11]. All these processes
contribute to deﬁne the epigenetic mechanisms by which gene expres-
sion is activated or silenced [12–16].
Post-translational modiﬁcations of histones occur at the N-terminal
tails of the protein chains and consist in covalent modiﬁcations that
are catalyzed by different classes of enzymes [17,18]. The ensemble of
thesemodiﬁcations is commonly referred as to be the histone code refer-
ring to the idea that all histone PTMs determine the activity state of an
underlying gene [19]. One of the hallmarks of the histone code is that
it can be positively or negatively correlatedwith speciﬁc transcriptional
states or organization of chromatin [20–23]. This is accomplished
through a ﬁne regulation of histone PTMs controlled by an enzymatic
machinery, which existence and function have been elucidated partly,
but with an extraordinary progression in the last years [23–29]. Impor-
tantly, further understanding of epigenetic phenomena occurring on
histone proteins is critical to shed light on biological processes that are
progressively translating into the development of new medical options
[29–31]. In this direction, different studies have highlighted how the
histone alterations contribute to the onset and growth of a variety of
cancers [7,23,24,27,32–41], amongother pathologies. Consequently, en-
zymes operating PTMs on histones are constituting attractive therapeu-
tic targets for the development of new therapies [13,31,42–44]. It
should be noted that, while the resulting effects on chromatin collec-
tively depend on the ensemble of histone PTMs, these are operated by
precise variations of physicochemical properties that we recently
reviewed [17]. For these reasons, large efforts from both academic and
industrial settings have been dedicated in the last year to identify and
evaluate new biologically active compounds against histone modifying
enzymes. Fuelled by the increasing availability of structural information,
several endeavors have been initiated and helped by the usage of
computer-aided molecular design techniques. Thus, in this mini-
review, we aim to highlight the aspects relating histone modiﬁcations
in the light of the future applications of computational techniques to
the research of new probe or lead-like epigenetic modulators.2. Type of Histone Modiﬁcations and Their Biological and
Clinical Relevance
To understand the relevance of computational techniques in
histone-related epigenetic targets, it is important to highlight
that these post-translational modiﬁcations are functionalizations/
defunctionalizations of speciﬁc residues, which are lysine, arginine, ser-
ine, threonine, histidine, tyrosine, cysteine and glutamic acid, located at
the N-terminal tails of each chain. Fig. 1 summarizes all the most com-
mon PTMs that can occur on histones. By far, lysine represents the res-
idues with most chemical versatility, as it is capable to undergo several
kinds and grades of modiﬁcations. Consequently, histone methyltrans-
ferases, demethylases, acetyltransferases and deacetylases have been
recently ascribed an important role as new classes of biological targets
for drug discovery [18,45–49]. Arginine represents also a residue that
is modiﬁed by enzymes recognized for drug development, in particular
histone methyltransferases. Differently to these previous cases, en-
zymes thatmodify histone serines, threonines, histidines, tyrosines, cys-
teines and glutamic acids have not been exploited yet for the discovery
of newmodulating compounds. Nevertheless, it is expected that further
elucidation of their biological role and protein structure will spur such
endeavors. It is worth to note that other kinds of modiﬁcations like
propionylation, butyrylation, crotonylation, 2-hydroxyisobutyrylation
have been reported [50].Different studies elucidate the impact that PTMs have on chromatin
and their relevance in human physiology and pathology [16,18,25,26,
31,51–57]. Interestingly, their biological role greatly varies, depending
on the kind of modiﬁcation. Therefore, for instance, the acetylation ap-
pears to be the most promiscuous histone modiﬁcation and is always
associated to transcriptional activity. Conversely, histone methylation
has a high degree of selectivity toward speciﬁc histone residues and
can be associated with both repression and transcription [58,59]. In ad-
dition PTMs can “cross-talk”, meaning that modiﬁcations can occur in a
concerted or a subsequent manner [25,60–63].
In the last decade, epigenetic modiﬁcations of histones have been
mainly studied in the context of cancer, particularly histone deacetylases
of classes I, II and IV (HDACs) [64]. Indeed, abnormal activity of the en-
zymes responsible for deacetylation of histones, modiﬁcation that alters
the chromatin structure repressing transcription, has been shown to be
implicated in several diseases [18,65]. Because of these compelling evi-
dences, HDACs have been recognized as consolidated drug target, in par-
ticular for breast cancer, colorectal cancer, leukemia, lymphoma, ovarian
and prostate cancer. In addition, another class of histone deacetylases
named sirtuins (or class III deacetylases), which uses NAD+ to catalyze
the removal of an acetyl group, also came into the light as new therapeutic
targets [66,67]. This family of enzymes, in fact,was found to be involved in
relevant physiological and pathological processes, as well as in aging-
related disorders, metabolic and inﬂammatory conditions and processes
involving DNA regulation and integrity, including cancer [68–71]. Inter-
estingly, also the correspondent families of enzymes that revert the cata-
lytic activity of histone deacetylation, i.e. acetyltransferases (HAT), have
also met a great deal of interest. Two classes of HAT exist and consist of
enzymes able to acetylatemultiple sites in the histone tails and additional
sites on the globular histone core, for the ﬁrst class, while the second class
mostly consists of cytoplasmic enzymes able to acetylate newly synthe-
sized histones prior to their deposition into chromatin. Abnormal regula-
tion of HATs has been linked to leukemia and several studies connecting
them to prostate and gastric cancers have been realized [72,73].
The secondmost studied histone modiﬁcation is methylation. As an-
ticipated above, protein methyltransferases (PMT) emerged recently as
new important targets for cancer therapy, since they were found to be
overexpressed or repressed in several types of cancer, precisely in breast
cancer, leukemia,myeloma, ovarian, prostate and kidney cancers. Sever-
al recently published reviews describe mechanism and biological roles
of PMTs [6,41,45,46,74–81]. Indeed, due to their importance in different
pathological conditions, several drug discovery programs have been
launched in order to design speciﬁc compounds able to modulate
these targets [46]. Equally, the recent focus in understanding histone
methylation led to the characterization of histone demethylases
(HDM). The ﬁrst described protein has been the lysine speciﬁc
demethylase 1 (LSD1) [82]. Soon after, a new class of proteins having
demethylase activity, the JMJC (Jumonji C) domain family, was discov-
ered and characterized [83]. LSD and JMJC demethylases have been re-
ported to be regulators of various cellular processes. Therefore, a
special effort, as in the case of PMTs, is currently made, aimed to the dis-
covery of small-molecule inhibitors with therapeutic potential [47,83].
Beside the above classes of enzymes, there is a mounting evidence
that also other type of modiﬁcations can constitute important paradigm
in epigenetics and may underlie new biological target for therapeutic
purposes. For instance, some studies highlighted speciﬁc roles of
ubiquitination [84–87], poly-ADP-ribosylation [88–96] and glycosyla-
tion [61,97–101] to the epigenetic code. However, the therapeutic po-
tential of these modiﬁcations still needs to be validated for the
therapeutic and drug discovery point of view. Equally, other modiﬁca-
tions like histone phosphorylation, citrullination (deamination) [102],
biotinylation [103,104], tail clipping and proline isomerization [25],
are still poorly understood and their role in human pathologies remains
largely unclear [25]. In the next paragraph,we aim to describe the state-
of-the-art of these modiﬁcations, analyzing, from a chemical point of
view, their role on the dynamics of histone proteins.
Fig. 1.Most common type of post-translational modiﬁcations occurring on histone proteins.
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The histone code collectively depends on the ensemble of post-
translational modiﬁcations that is operated at the chromatin level, by
single variations of physicochemical properties of the modiﬁed resi-
dues. Consequently, the microenvironment and the biochemical differ-
ences obtained by PTMs depend on the attachment or removal of
chemical functional groups, whose enzymes, mechanisms of action
and cofactors are overviewed in Table 1. We recently proposed that,
from a chemical functionality point of view, histone PTMs can be divid-
ed in two main groups [17]. The ﬁrst group I encompassing PTMs lead-
ing to the addition or the removal of monofunctional, generally small,
organic substituents and a second group including polyfunctional, and
in some case elaborate and large, organic molecules. Both groups are
composed of writer or eraser enzymes, i.e. which add or remove from
histone residues speciﬁc substituents.
Modiﬁcations of the ﬁrst group are acetylation, methylation, phos-
phorylation, deimination and palmitoylation (acylation). As seen
above, acetylation is the most common and studied PTM and consists
in the addition of an acetyl group on a lysine residue mediated by two
major classes of histone acetyltransferases (HAT), Type-A (whichincludes GNAT, p300/CBP, and MYST) and Type-B [18,65,72]. This func-
tion can be removed by two categories of different catalytic activity en-
zymes: classes I, II and IV histone deacetylases (HDAC) and class III
deacetylases, also known as sirtuins (SIRT) that work with a NAD+-
dependent mechanism [105].
Methylation is the second most common PTM and lysine, as seen
above, is the residue that undergoes the widest number of methylation
reactions. Indeed, lysine can bemono-, di-, or tri-methylated by histone
methyltransferases (HMT, also known as PKMT). HMTs can also mono-
or di-methylate arginines and this class of enzymes is commonly re-
ferred to as protein arginine methyltransferases (PRMT) [106]. Methyl
groups can be erased only from lysines through the action of histone
demethylases (HDM or, in the case of lysines, KDM). Phosphorylation
of histone has been observed on serine, threonine [107], tyrosine
[107] and histidine [108] sites while phosphatases, which hydrolyze
the phosphoric monoesters or monoamides restoring the original resi-
dues, represent the erasers of this histonemodiﬁcation. Deimination oc-
curs on arginines and methylarginines through the catalysis of
peptidylarginine deiminases (PAD) [109].
Modiﬁcations of the second group are ubiquitylation, SUMOylation,
biotinylation, glycosylation and ADP-ribosylation. While, in principle,
Table 1
Mechanisms of histone modiﬁcations.
Histone modiﬁcation Cofactor Leaving group Target residue Substituents Operating enzyme Type of enzyme
Acetylation Acetyl-CoA CoA Lys HAT Writer
Deacetylation Zn2+, Fe2+, Co2+, Mn2+ CH3COO− Ac-Lys HDAC Eraser
NAD+ OAADPr Ac-Lys SIRT Eraser
Palmitoylation – – Cys – Writer
Methylation SAM SAH Arg, Lys PMT Writer
Demethylation FAD HCHO Me-Lys LSD Eraser
Me2-Lys
Fe2+, α-KG HCHO Me-Lys PHF8 Eraser
Me2-Lys JmjD
Me3-Lys JHDM
Citrullination/deimination Ca2+ NH3 Arg PAD Writer
Me-Arg




Dephosphorylation – – Phos-Ser Phosphatase
Phos-Thr
ADP-ribosylation NAD+ NAM Lys ADP-ribosyltransferase, SIRT4, SIRT6 Writer
Glu
Glycosylation (O-GlcNAcylation) UDP-GlcNAc UDP Ser OGT Writer
Thr
Biotinylation – – Lys Biotin-protein ligase Writer
Ubiquitination ATP – Lys E1, E2, E3 proteins Writer
Deubiquitination – – Ub-Lys Histone H2A deubiquitinase Eraser
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is worth to note that decitrullination, depalmitoylation, deADP-
ribosylation, debiotinylation and deglycosylation have not been de-
scribed, yet. Mono- or poly-ADP-ribosylation is catalyzed by ADP-
ribosyltransferases (ART), clostridia-toxin-like (ARTC) or diphtheria
toxin-like (ARTD), which are most commonly known as PARP, and
some sirtuin isoforms (Table 1) [88,110,111]. Biotinylation and glyco-
sylation are still poorly characterized and have been linked to the his-
tone code recently [97,99,112,113]. Ubiquitylation takes place by the
action of E1, E2, and E3 enzymes,which catalyze the addition of anubiq-
uitin (Ub) molecule to the target lysine via an isopeptide bond. The re-
versal of this action is operated by deubiquitylating enzymes (DUB), so
far demonstrated to act only on histones H2A and H2B. SUMO (Small
Ubiquitin-like MOdiﬁer) proteins can be added on lysine residues in a
similar way.
4. Molecular Design Techniques Applied to Histone
Modifying Enzymes
Computer-aided molecular techniques are widely used in academia
and industrial settings to assist the selection of new compounds that can
modulate biological targets. Several examples testify their successful ap-
plications in the development of new chemical entities [114–116] and a
wide range of disciplines, including chemoinformatics, computational
chemistry, structural biology, biophysics, medicinal chemistry, organic
chemistry and pharmacology, is at disposal of scientists working in
these ﬁelds. When applied to the discovery of compounds supposed to
become future drugs, these techniques are commonly referred as
computer-aided drug design (CADD) techniques. Certainly, among
them, virtual screening acquired the greatest popularity due to its abil-
ity to screen rapidly and cost-effectively large libraries of chemical com-
pounds [117–119]. CADD techniques can be divided in two categories:
ligand-based and structure-based drug design techniques (LBDD and
SBDD), even if this classiﬁcation is becoming nowadays loose, as several
techniques offer technical advantages that are proper of both categories.The ﬁrst category usually takes advantage of the information of known
bioactive compounds (ligands), while the second usually exploit three-
dimensional structure of the biological target (protein), in order to iden-
tify new small-moleculemodulators of the protein activity. The growing
availability of protein structures resolved by X-ray crystallography or
NMR technique has progressively raised the possibility to deploy
SBDD.However, ligand-based techniques still constitute useful tools, es-
pecially when the structural information of a biological target is missing
or when the molecular design effort is not directed toward a target-
centric approach. Studies aimed at the modulation of cellular pathways
or speciﬁc phenotypic traits without a precise knowledge of the mech-
anism of action are representative of this case.
In the context of epigenetics, the research oriented toward the de-
velopment of new therapeutically-relevant molecules has ﬂourished
in the last years. Several works report rationales, targets, drugs, ap-
proaches, compounds, tools and methodologies [32,120]. In addition,
different reviews reporting the approaches for the discovery of new
epidrugs or chemical probes for epigenetic targets have beenwritten re-
cently [18,56,57,121,122]. An intriguing aspect in this ﬁeld of research is
the fast pace aimed to extend the discovery of new compounds to
epitargets that are currently not validated and that may offer new per-
spective for the generation of new therapeutic agents. In this direction,
particular aspect of epigenetics, for instance, the modulation of the
microRNA biogenesis pathway, have been recognized as new possible
way to achieve therapeutic target for human disease, in particular can-
cer [9,123–125].
In all this framework of research, computational techniques are
playing a progressive role to help the identiﬁcation of new molecular
entities for epigenetic targets. Different techniques have been used to
identify new modulating compounds and to explain, mechanism of ac-
tions, binding modes and protein dynamics [22,80,126–129]. Most of
the research in this direction has beendone on classes I, II and IV histone
deacetylases. Indeed, a variety of quantitative structure–activity rela-
tionship (QSAR) studies and computational works, elucidating retro-
spectively protein dynamics, binding modes, binding afﬁnities and
362 F. Andreoli, A. Del Rio / Computational and Structural Biotechnology Journal 13 (2015) 358–365selectivity among HDAC isoforms, have been published [130–139]. For
instance, a recent and prospective work has been done to identify new
inhibitors of SchistosomamansoniHDAC8bymeans of homologymodel-
ing, molecular dynamics and molecular docking techniques [140]. It is
interesting to note that most of the prospective works have been ap-
plied on other epigenetic targets than HDACs, reﬂecting the idea that
computational techniques are useful tool to help the identiﬁcation of
new biologically active compounds for investigational epigenetic tar-
gets. In this direction two molecular docking studies have been applied
onHAT p300, resulting on the identiﬁcation of two classes of new inhib-
itors: benzothiazines and pyrazolone exomethylene vinyl compounds
(1 and2, Fig. 2) [141,142]. Prospective high-throughput docking screen-
ing and computational studies with molecular dynamic simulations
were performed on LSD1, leading to the identiﬁcation of nanomolar
N′-(1-phenylethylidene)-benzohydrazides (3, Fig. 2) and novel classes
of short peptide inhibitors [143–146]. LSD1was also object of retrospec-
tive studies based on virtual screening procedures, aiming at elucidating
ligand selectivity with a closely related target, theMAO-B [147] and ex-
tended molecular dynamic simulations were used to highlight new po-
tential binding regions for drug-like molecules, peptides, protein
partners and chromatin [144]. Docking studies were also applied to
identify new KDM4B inhibitors, which demonstrated an activity in the
lowmicromolar range of concentration (4, Fig. 2), and Sirt1/Sirt2 inhib-
itors, like thiobarbiturates (5, Fig. 2) [148,149].We also recently applied
these techniques to the identiﬁcation of new and selective inhibitors of
Sirt6 (6, Fig. 2) [150]. Interestingly, pharmacophore techniques have
been used less frequently than docking techniques on histone modify-
ing enzymes. A successful applicative example of the ﬁrst technique
has been published by Sippl and colleagues for the identiﬁcation of
new PRMT1 inhibitors, which were found through a pharmacophoreFig. 2. Representative molecular entities able to interfere with histone modifying enzymes. M
(http://www.chemaxon.com).hypothesis built on the basis of the PRMT1–allantodapsone interaction
model (7, Fig. 2) [151].
Computational chemistry and protein modeling is also actively
supporting the basic research on epigenetic targets. A valuable example
is the set of tools that are currently used to for detect protein plasticity,
dynamics of catalytic sites, analysis of allosteric pockets and interactions
with other proteins that may constitute a useful way to study new pro-
tein–protein inhibitors (PPI). Some recent reviews discussing these as-
pects have been written recently on HDACs and other epigenetic
players [152–154]. Interestingly, also quantum mechanical methods
like QM/MM or DFT have found utility in this ﬁeld, especially to explore
the role metal-containing enzymes and their inﬂuence on catalytic ac-
tivities and the inhibition mechanism by small-molecule modulators
[155–157]. Combined computational techniques have been also suc-
cessfully exploited for the de novo design of inhibitory peptides for his-
tone methyltransferase [158] and chemoinformatic data mining tools
like self-organizing maps (SOM) have been exploited for the computa-
tional prediction of common non-epigenetic drugs as epigenetic modu-
lators [159]. It is worth to note also that emerging works driven by
computational-based techniques are also starting to focus on food and
natural components, known to be able to inﬂuence the epigenetic
code [37,160–164]. Indeed, dietary components like complementary
and/or alternative medicines from green tea, genistein from soybean,
isothiocyanates from plant foods, curcumin from turmeric, resveratrol
from grapes, and sulforaphane from cruciferous vegetables, have been
studied for their ability to target the epigenome, especially in different
cancer pathologies [18]. Nevertheless, the mechanisms of action of
these compounds are still poorly understood and computer-aided tech-
niques are expected to help the comprehension of thesemechanisms. In
particular, we believe that the availability of compound databases ofarvin was used for drawing and displaying chemical structures, Marvin 6.0.0, ChemAxon
363F. Andreoli, A. Del Rio / Computational and Structural Biotechnology Journal 13 (2015) 358–365natural and dietary sources could constitute an effective step toward the
identiﬁcation, development and pharmacological deﬁnition of natural
and dietary-derived components, affecting epigenetic mechanism, that
hold the advantage of pharmaceutical formulation based on natural-
occurring scaffold.
5. Summary and Outlook
Major research efforts are currently directed toward the discovery of
new small-molecules able tomodulate epigenetic writers or erases that
are involved in chromatin remodeling. Recent successful stories docu-
ment the possibility to interfere with the epigenetic codewith small or-
ganic molecules. Indeed, ﬁrst pre-clinical and clinical results, especially
for HDACs, testify thatmany other epidrugsmight be effective as combi-
nation therapies to control the process of genesis and progression of
several forms of cancer, among other pathologies. It is unquestionable
that epigenetics framework will play a major role in the near future to
develop new therapies against these diseases and molecular design
techniques offer the chance to tackle these challenges.
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